Use of PCSK9 inhibitors is not associated with adverse cognitive effects, even among patients who attain very low levels of LDL cholesterol, according to a study in a subgroup of 1,204 patients from the FOURIER trial, a randomized trial of the PCSK9 inhibitor evolocumab added

中文翻译：

---

血脂异常：PCSK9抑制剂对认知功能无影响

一项来自FOURIER试验的1,204名患者亚组的研究表明，即使在LDL胆固醇水平非常低的患者中，使用PCSK9抑制剂也不会带来不利的认知作用，该研究是PCSK9抑制剂evolocumab的一项随机试验